Product Browser

Last updated: 2016/11/27

Product Compare

Product Compare Cancel Click this icon to add products to compare list. Select up to 10 products.

Quick Order (Tutorial)

Input Catalog #,
place order here!
Catalog # :
  • Where to buy
  • Choose your location

FMR1 Validated Chimera RNAi

  • Catalog # : H00002332-R01V
  • Visit Frequency :
  • Countries :
  • Specification
  • Product Description:
  • Homo sapiens fragile X mental retardation 1 (FMR1), mRNA.
  • Reactivity:
  • Human
  • Supplied Product:
  • DEPC water
  • Target Refseq:
  • NM_002024
  • Storage Instruction:
  • Store at -20°C, do not exceed 4 - 5 freeze-thaw cycles to ensure product integrity.
  • Note:
  • Position of the Chimera RNAi.

  • Publication Reference
  • Applications
  • RNAi Knockdown (Antibody validated)
  • RNAi Knockdown (Antibody validated)
  • Western blot analysis of FMR1 over-expressed 293 cell line, cotransfected with FMR1 Validated Chimera RNAi ( Cat # H00002332-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with FMR1 monoclonal antibody (M01), clone 2D4 (Cat # H00002332-M01 ). GAPDH ( 36.1 kDa ) used as specificity and loading control.
  • PDF DownloadProtocol Download
  • Application Image
  • RNAi Knockdown (Antibody validated)
  • RNAi Knockdown (Antibody validated)
  • enlarge
  • Gene Information
  • Entrez GeneID:
  • 2332
  • Gene Name:
  • FMR1
  • Gene Alias:
  • FMRP,FRAXA,MGC87458,POF,POF1
  • Gene Description:
  • fragile X mental retardation 1
  • Gene Summary:
  • The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm. A trinucleotide repeat (CGG) in the 5' UTR is normally found at 6-53 copies, but an expansion to 55-230 repeats is the cause of fragile X syndrome. Expansion of the trinucleotide repeat may also cause one form of premature ovarian failure (POF1). [provided by RefSeq
  • Other Designations:
  • OTTHUMP00000024197,premature ovarian failure 1
  • RSS
  • YouTube
  • Linkedin
  • Facebook